Blood Cancer

Category

Morristown Medical Center Recruits Waldenström Macroglobulinemia Patients for Advanced Kinase Inhibitor from Beigene

Patients diagnosed with Waldenström macroglobulinemia in north and central New Jersey may have an option for an experimental treatment. Morristown Medical Center’s Carol G. Simon Cancer Center is participating in a new clinical trial offering local New Jersey-based...

Cleveland Clinic Investigator Proposes Relaxing Eligibility Criteria for MDS Clinical Trial Participation

Recently the Cleveland Clinic’s Abby Statler discussed eligibility criteria exclusions for MDS clinical trials. She reports that observed outcomes indicate that eligibility criteria for patients with MDS relevant to liver function, renal function, and comorbidities...

Jun Zhu, MD, PhD with Beijing University Cancer Hospital Principal Investigator for Brukinsa

Recently, BeiGene Ltd’s lymphoma treatment Brukinsa was approved by the U.S. Food and Drug Administration. This is the first time a drug developed predominantly in China by a Chinese biopharma sponsor has been approved within America. The key clinical trials...

Acalabrutinib(Calquence) Monotherapy Active in Waldenstrom Macroglobulinemia in Phase II—More Study Needed

Led by Dr. Roger G. Owen, St. James’ University Hospital, Leeds, UK, and colleagues recently concluded that for those patients with treatment-naïve or relapsed/refractory Waldrenstrom Macroglobulinemia (WM), a type of non-Hodgkin lymphoma, single-agent acalabrutinib...

St. Jude Children’s Research Hospital Clinical Trial Results Reduce Rate of Relapse for Children with Acute Lymphoblastic Leukemia (ALL)

St. Jude Children’s Research Hospital concluded the Total Therapy Study 16 evidencing the ability to successfully reduce the rate of central nervous system (CNS) relapse to 1.8% for acute lymphoblastic leukemia (ALL) in children. The Problem: ALL Relapse Despite...

Pin It on Pinterest